LONG-TERM OUTCOMES OF PHOTODYNAMIC THERAPY WITH TALAPORFIN SODIUM FOR LOCAL FAILURE OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER CHEMORADIOTHERAPY

Tomonori Yano

UEG Week Copenhagen 2023 | Poster

Oesophagus

October 17, 2023

Retrospective study of 108 patients found photodynamic therapy with talaporfin sodium achieved 58.8% local complete response for esophageal squamous cell carcinoma local failure after chemoradiotherapy, with 78.1% three-year overall survival and no grade 3 or higher adverse events.

KEY POINTS

- Among 108 patients treated with photodynamic therapy using talaporfin sodium for local failure after chemoradiotherapy or radiotherapy, 60 patients (58.8%) achieved local complete response over a median 23-month follow-up.
- Three-year overall survival was 78.1% for all patients and significantly better for those achieving local complete response compared to those who did not (89.3% versus 67.7%, P=0.003).
- Lesions smaller than 20 mm and involving less than half the esophageal circumference were significantly more likely to achieve local complete response (80.0% versus 45.2% and 64.4% versus 16.7%, respectively).
- No grade 3 or higher adverse events occurred; non-cardiac chest pain was most common (60.2%), while skin phototoxicity (4.6%) and esophageal stricture requiring dilatation (4.7%) were infrequent.
- This material is relevant for clinicians managing esophageal squamous cell carcinoma patients with local failure after chemoradiotherapy who refuse or are unsuitable for salvage esophagectomy.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/e131f2be-743b-11ee-a373-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.